Vimarsana
Biggest News Aggregation in the World

Page 3 - Human Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Human Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Human Pharma Today - Breaking & Trending Today

Boehringer Ingelheim introduces NexGard SPECTRA® for dogs in India - Vimarsana News

Boehringer Ingelheim introduces NexGard SPECTRA® for dogs in India

(This story has not been edited by THE WEEK and is auto-generated from a PTI

Source: theweek.in
Empagliflozin Shows 10% Relative Risk Reduction in Time to First Hospitalization Due to Heart Failure - Vimarsana News

Empagliflozin Shows 10% Relative Risk Reduction in Time to First Hospitalization Due to Heart Failure

The finding did not reach statistical significance in the primary composite endpoint.

Boehringer Ingelheim Named Official Animal Health Company Partner of the Atlanta Braves - Vimarsana News

Boehringer Ingelheim Named Official Animal Health Company Partner of the Atlanta Braves

/PRNewswire/ -- Boehringer Ingelheim, the largest animal health company in Georgia, is proud to announce its new partnership with the Atlanta Braves and the...

Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet - Vimarsana News

Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet

/CNW/ - For the past six months, inpatients receiving care at Vancouver Coastal Health's (VCH) Vancouver General Hospital have been able to fuel their healing...

Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia - Vimarsana News

Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia

Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaSosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties Ingelheim, Germany, Tokyo, Japan and Cambridge, UK,

Source: yahoo.com